Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens

The cell‐surface receptor tyrosine kinase protein c‐erbB‐2 is immunocytochemically detected as membrane staining on the surface of cancer cells in 20–30% of cases of breast cancer, and its presence has been associated with poor prognosis for the patient. However, there have been numerous reports of...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 1998-05, Vol.76 (4), p.459-463
Main Authors: Taylor, Susan L., Platt‐Higgins, Angela, Rudland, Philip S., Winstanley, John H. R., Barraclough, Roger
Format: Article
Language:English
Subjects:
Biological and medical sciences
Breast Neoplasms - metabolism
Breast Neoplasms - ultrastructure
Cytoplasm - metabolism
Genital system. Mammary gland
Humans
Immunohistochemistry
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Polymerase Chain Reaction
Receptor, ErbB-2 - metabolism
RNA, Messenger - analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c4242-3e82b3deb2e408fa94b8f29791702b3a5b346d726155208d03da081c3133e8773
container_end_page 463
container_issue 4
container_start_page 459
container_title International journal of cancer
container_volume 76
creator Taylor, Susan L.
Platt‐Higgins, Angela
Rudland, Philip S.
Winstanley, John H. R.
Barraclough, Roger
description The cell‐surface receptor tyrosine kinase protein c‐erbB‐2 is immunocytochemically detected as membrane staining on the surface of cancer cells in 20–30% of cases of breast cancer, and its presence has been associated with poor prognosis for the patient. However, there have been numerous reports of immunocytochemical staining for c‐erbB‐2 solely in the cytoplasm of some normal and tumour specimens with frequently used anti‐sera, and the presence of such staining has been difficult to interpret. It is not known for certain that cytoplasmic c‐erbB‐2 staining is an artefact of the immunocytochemical procedures used. Thus, mRNA for c‐erbB‐2 has been quantified in tumours exhibiting only cytoplasmic staining or varying levels of membrane staining using a sensitive, competitive PCR method. Whereas abundant levels of c‐erbB‐2 mRNA are found in tumours exhibiting membrane staining for c‐erbB‐2 and these levels correlate with the percentage of tumour cells showing membranous staining for c‐erbB‐2, the level of c‐erbB‐2 mRNA in tumours displaying only cytoplasmic staining is no higher than in c‐erbB‐2‐negative specimens. Int. J. Cancer 76:459–463, 1998.© 1998 Wiley‐Liss, Inc.
doi_str_mv 10.1002/(SICI)1097-0215(19980518)76:4<459::AID-IJC2>3.0.CO;2-Q
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79878792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16411584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4242-3e82b3deb2e408fa94b8f29791702b3a5b346d726155208d03da081c3133e8773</originalsourceid><addsrcrecordid>eNqFkdtqFEEURRtR4hj9BKEeRJKHHuvWXV2jBMaOl5HgEG-vh-rq06akb3b1EOYt4A_4jX6J1WYcEYU8nSrO3pvNWVF0wuicUcqfHL1f5atjRrWKKWfJEdM6ownLjlW6kM9koheL5eo0Xr3J-YmY03m-fsrj81vRbG-5Hc1CEI0VE-nd6J73XyhlLKHyIDrQiQ5vNYu-5dux62vjG2eJH41rXfuZdBWxP66-41A8D4MT50nbjcR431lnRizJpRsvyHiBpB_QY2tx8pQ4oh1NUePf9ubd2yVxLSkGNH4k1gT9QHyP1jXY-vvRncrUHh_s5mH08eWLD_nr-Gz9apUvz2IrueSxwIwXosSCo6RZZbQssoprpZmiYWGSQsi0VDxlScJpVlJRGpoxK5gIVqXEYfT4Orcfuq8b9CM0zlusa9Nit_GgdKYypfmNQpbKcMhMBuGna6EdOu8HrKAfXGOGLTAKE0aACSNMTGBiAr8xgkpBQsAIEDDChBEEUMjXwOE8BD_cNdgUDZb72B23sH-02xtvTV0N4aTO72Wcc0ZT_qffpatx-0-5G7v9p9qvv_gJAbjHVA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16411584</pqid></control><display><type>article</type><title>Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Taylor, Susan L. ; Platt‐Higgins, Angela ; Rudland, Philip S. ; Winstanley, John H. R. ; Barraclough, Roger</creator><creatorcontrib>Taylor, Susan L. ; Platt‐Higgins, Angela ; Rudland, Philip S. ; Winstanley, John H. R. ; Barraclough, Roger</creatorcontrib><description>The cell‐surface receptor tyrosine kinase protein c‐erbB‐2 is immunocytochemically detected as membrane staining on the surface of cancer cells in 20–30% of cases of breast cancer, and its presence has been associated with poor prognosis for the patient. However, there have been numerous reports of immunocytochemical staining for c‐erbB‐2 solely in the cytoplasm of some normal and tumour specimens with frequently used anti‐sera, and the presence of such staining has been difficult to interpret. It is not known for certain that cytoplasmic c‐erbB‐2 staining is an artefact of the immunocytochemical procedures used. Thus, mRNA for c‐erbB‐2 has been quantified in tumours exhibiting only cytoplasmic staining or varying levels of membrane staining using a sensitive, competitive PCR method. Whereas abundant levels of c‐erbB‐2 mRNA are found in tumours exhibiting membrane staining for c‐erbB‐2 and these levels correlate with the percentage of tumour cells showing membranous staining for c‐erbB‐2, the level of c‐erbB‐2 mRNA in tumours displaying only cytoplasmic staining is no higher than in c‐erbB‐2‐negative specimens. Int. J. Cancer 76:459–463, 1998.© 1998 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/(SICI)1097-0215(19980518)76:4&lt;459::AID-IJC2&gt;3.0.CO;2-Q</identifier><identifier>PMID: 9590117</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Biological and medical sciences ; Breast Neoplasms - metabolism ; Breast Neoplasms - ultrastructure ; Cytoplasm - metabolism ; Genital system. Mammary gland ; Humans ; Immunohistochemistry ; Investigative techniques, diagnostic techniques (general aspects) ; Medical sciences ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Polymerase Chain Reaction ; Receptor, ErbB-2 - metabolism ; RNA, Messenger - analysis</subject><ispartof>International journal of cancer, 1998-05, Vol.76 (4), p.459-463</ispartof><rights>Copyright © 1998 Wiley‐Liss, Inc.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4242-3e82b3deb2e408fa94b8f29791702b3a5b346d726155208d03da081c3133e8773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2221062$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9590117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taylor, Susan L.</creatorcontrib><creatorcontrib>Platt‐Higgins, Angela</creatorcontrib><creatorcontrib>Rudland, Philip S.</creatorcontrib><creatorcontrib>Winstanley, John H. R.</creatorcontrib><creatorcontrib>Barraclough, Roger</creatorcontrib><title>Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>The cell‐surface receptor tyrosine kinase protein c‐erbB‐2 is immunocytochemically detected as membrane staining on the surface of cancer cells in 20–30% of cases of breast cancer, and its presence has been associated with poor prognosis for the patient. However, there have been numerous reports of immunocytochemical staining for c‐erbB‐2 solely in the cytoplasm of some normal and tumour specimens with frequently used anti‐sera, and the presence of such staining has been difficult to interpret. It is not known for certain that cytoplasmic c‐erbB‐2 staining is an artefact of the immunocytochemical procedures used. Thus, mRNA for c‐erbB‐2 has been quantified in tumours exhibiting only cytoplasmic staining or varying levels of membrane staining using a sensitive, competitive PCR method. Whereas abundant levels of c‐erbB‐2 mRNA are found in tumours exhibiting membrane staining for c‐erbB‐2 and these levels correlate with the percentage of tumour cells showing membranous staining for c‐erbB‐2, the level of c‐erbB‐2 mRNA in tumours displaying only cytoplasmic staining is no higher than in c‐erbB‐2‐negative specimens. Int. J. Cancer 76:459–463, 1998.© 1998 Wiley‐Liss, Inc.</description><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - ultrastructure</subject><subject>Cytoplasm - metabolism</subject><subject>Genital system. Mammary gland</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Medical sciences</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Polymerase Chain Reaction</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>RNA, Messenger - analysis</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFkdtqFEEURRtR4hj9BKEeRJKHHuvWXV2jBMaOl5HgEG-vh-rq06akb3b1EOYt4A_4jX6J1WYcEYU8nSrO3pvNWVF0wuicUcqfHL1f5atjRrWKKWfJEdM6ownLjlW6kM9koheL5eo0Xr3J-YmY03m-fsrj81vRbG-5Hc1CEI0VE-nd6J73XyhlLKHyIDrQiQ5vNYu-5dux62vjG2eJH41rXfuZdBWxP66-41A8D4MT50nbjcR431lnRizJpRsvyHiBpB_QY2tx8pQ4oh1NUePf9ubd2yVxLSkGNH4k1gT9QHyP1jXY-vvRncrUHh_s5mH08eWLD_nr-Gz9apUvz2IrueSxwIwXosSCo6RZZbQssoprpZmiYWGSQsi0VDxlScJpVlJRGpoxK5gIVqXEYfT4Orcfuq8b9CM0zlusa9Nit_GgdKYypfmNQpbKcMhMBuGna6EdOu8HrKAfXGOGLTAKE0aACSNMTGBiAr8xgkpBQsAIEDDChBEEUMjXwOE8BD_cNdgUDZb72B23sH-02xtvTV0N4aTO72Wcc0ZT_qffpatx-0-5G7v9p9qvv_gJAbjHVA</recordid><startdate>19980518</startdate><enddate>19980518</enddate><creator>Taylor, Susan L.</creator><creator>Platt‐Higgins, Angela</creator><creator>Rudland, Philip S.</creator><creator>Winstanley, John H. R.</creator><creator>Barraclough, Roger</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19980518</creationdate><title>Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens</title><author>Taylor, Susan L. ; Platt‐Higgins, Angela ; Rudland, Philip S. ; Winstanley, John H. R. ; Barraclough, Roger</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4242-3e82b3deb2e408fa94b8f29791702b3a5b346d726155208d03da081c3133e8773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - ultrastructure</topic><topic>Cytoplasm - metabolism</topic><topic>Genital system. Mammary gland</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Medical sciences</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Polymerase Chain Reaction</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>RNA, Messenger - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taylor, Susan L.</creatorcontrib><creatorcontrib>Platt‐Higgins, Angela</creatorcontrib><creatorcontrib>Rudland, Philip S.</creatorcontrib><creatorcontrib>Winstanley, John H. R.</creatorcontrib><creatorcontrib>Barraclough, Roger</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taylor, Susan L.</au><au>Platt‐Higgins, Angela</au><au>Rudland, Philip S.</au><au>Winstanley, John H. R.</au><au>Barraclough, Roger</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>1998-05-18</date><risdate>1998</risdate><volume>76</volume><issue>4</issue><spage>459</spage><epage>463</epage><pages>459-463</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>The cell‐surface receptor tyrosine kinase protein c‐erbB‐2 is immunocytochemically detected as membrane staining on the surface of cancer cells in 20–30% of cases of breast cancer, and its presence has been associated with poor prognosis for the patient. However, there have been numerous reports of immunocytochemical staining for c‐erbB‐2 solely in the cytoplasm of some normal and tumour specimens with frequently used anti‐sera, and the presence of such staining has been difficult to interpret. It is not known for certain that cytoplasmic c‐erbB‐2 staining is an artefact of the immunocytochemical procedures used. Thus, mRNA for c‐erbB‐2 has been quantified in tumours exhibiting only cytoplasmic staining or varying levels of membrane staining using a sensitive, competitive PCR method. Whereas abundant levels of c‐erbB‐2 mRNA are found in tumours exhibiting membrane staining for c‐erbB‐2 and these levels correlate with the percentage of tumour cells showing membranous staining for c‐erbB‐2, the level of c‐erbB‐2 mRNA in tumours displaying only cytoplasmic staining is no higher than in c‐erbB‐2‐negative specimens. Int. J. Cancer 76:459–463, 1998.© 1998 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>9590117</pmid><doi>10.1002/(SICI)1097-0215(19980518)76:4&lt;459::AID-IJC2&gt;3.0.CO;2-Q</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0020-7136
ispartof International journal of cancer, 1998-05, Vol.76 (4), p.459-463
issn 0020-7136
1097-0215
language eng
recordid cdi_proquest_miscellaneous_79878792
source Wiley-Blackwell Read & Publish Collection
subjects Biological and medical sciences
Breast Neoplasms - metabolism
Breast Neoplasms - ultrastructure
Cytoplasm - metabolism
Genital system. Mammary gland
Humans
Immunohistochemistry
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Polymerase Chain Reaction
Receptor, ErbB-2 - metabolism
RNA, Messenger - analysis
title Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T11%3A36%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytoplasmic%20staining%20of%20c%E2%80%90erbB%E2%80%902%20is%20not%20associated%20with%20the%20presence%20of%20detectable%20c%E2%80%90erbB%E2%80%902%20mRNA%20in%20breast%20cancer%20specimens&rft.jtitle=International%20journal%20of%20cancer&rft.au=Taylor,%20Susan%20L.&rft.date=1998-05-18&rft.volume=76&rft.issue=4&rft.spage=459&rft.epage=463&rft.pages=459-463&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/(SICI)1097-0215(19980518)76:4%3C459::AID-IJC2%3E3.0.CO;2-Q&rft_dat=%3Cproquest_cross%3E16411584%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4242-3e82b3deb2e408fa94b8f29791702b3a5b346d726155208d03da081c3133e8773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16411584&rft_id=info:pmid/9590117&rfr_iscdi=true